Stage II DTC: mortality rate sharply higher in younger patients

  • Liu Z & al.
  • J Clin Endocrinol Metab
  • 22 May 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Younger age is associated with increased mortality risk of patients with American Joint Committee on Cancer (AJCC) stage II differentiated thyroid cancer (DTC).

Why this matters

  • Stage II patients are often perceived as low-risk and receive conservative treatment.

Key results

  • Using AJCC versions 6.0 and 7.0, age
  • DTC-specific survival for patients with stage II disease aged
  • Using AJCC version 8.0, age
  • DTC-specific survival for patients with stage II disease aged
  • Study design

    • Patients with DTC from the USA Surveillance, Epidemiology, and End Results database were included.
    • Funding: NIH.

    Limitations

    • Retrospective analysis of large database.